603739 Qingdao Vland Biotech INC.
- 12.65
- -0.01-0.08%
Qingdao Vland Biotech INC. News
Some Qingdao Vland Biotech INC. (SHSE:603739) Shareholders Look For Exit As Shares Take 27% Pounding
Qingdao Vland Biotech INC. (SHSE:603739) shares have retraced a considerable 27% in the last month, reversing a fair amount of their solid recent performance. The last month has meant the stock is
Qingdao Vland Biotech INC.'s (SHSE:603739) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Most readers would already be aware that Qingdao Vland Biotech's (SHSE:603739) stock increased significantly by 45% over the past three months. But the company's key financial indicators appear to b
Azure Biotech (603739.SH) will distribute the 2023 cash dividend of 0.1 yuan per share on May 30
Azure Biotech (603739.SH) announced that the company will release the 2023 fiscal year on May 30, 2024...
The stock price has doubled since April 25th! Azure Creatures (603739.SH): There may be irrational hype
Blue Biotech (603739.SH) announced that the company's shares will be traded for 10 consecutive trading days (April 25, 2024...
Cumulative stock price increase of more than 100% Blue Bio (603739.SH): There are no conditions for industrialization in the field of synthetic biology
On May 9, Ge Longhui (603739.SH) announced serious abnormal fluctuations in stock trading. The cumulative deviation value of the company's stock closing price increase exceeded 100% within 10 consecutive trading days (April 25, 2024 to May 9, 2024). According to the relevant provisions of the “Shanghai Stock Exchange Trading Rules”, this is a serious abnormal fluctuation in stock trading. Recently, the company noticed that the Internet and some media published reports on “synthetic biology.” The company has set up only 1 synthetic biotechnology innovation laboratory in the field of synthetic biology, which is mainly used to develop feed functionality
Blue Biology (603739.SH): The company has set up only 1 synthetic biotechnology innovation laboratory in the field of synthetic biology
Blue Biotech (603739.SH) announced that the company's stock has been rising and stopping for 5 consecutive trading days, and the stock price has fluctuated recently...
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings
Unsurprisingly, Qingdao Vland Biotech INC.'s (SHSE:603739) stock price was strong on the back of its healthy earnings report. However, our analysis suggests that shareholders may be missing some fact
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
What Qingdao Vland Biotech INC.'s (SHSE:603739) 26% Share Price Gain Is Not Telling You
Qingdao Vland Biotech INC. (SHSE:603739) shares have continued their recent momentum with a 26% gain in the last month alone. Unfortunately, despite the strong performance over the last month, the
Weilan Biotech (603739.SH) released 2023 results, with net profit of 80.7069 million yuan, an increase of 15.56% over the previous year
According to the Zhitong Finance App, Weilan Biotech (603739.SH) released its 2023 annual report, achieving revenue of 1,199 billion yuan, an increase of 3.07% over the previous year. Net profit attributable to shareholders of listed companies was RMB 807.069 million, an increase of 15.56% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 42.1788 million yuan, an increase of 6.21% over the previous year. It is proposed to distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares to all shareholders.
Qingdao Vland Biotech (SHSE:603739) Stock Falls 18% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. To wit, the Qingdao Vland Biotech INC. (SHSE:603739) share price managed to fall 60
Blue Bio (603739.SH): No weight loss related probiotics
Gelonghui, Feb. 19: Weilan Biotech (603739.SH) said on the investor interactive platform that up to now, the company has no probiotics related to weight loss.
Qingdao Vland Biotech INC.'s (SHSE:603739) P/E Is On The Mark
Qingdao Vland Biotech INC.'s (SHSE:603739) price-to-earnings (or "P/E") ratio of 41.2x might make it look like a sell right now compared to the market in China, where around half of the companies hav
Blue Bio (603739.SH): Obtained a new veterinary drug registration certificate
On January 19, Ge Longhui (603739.SH) announced that according to the “Veterinary Drug Administration Regulations” and the “Veterinary Drug Registration Measures”, after review by the Ministry of Agriculture and Rural Affairs, it was approved by Qingdao Weilan Biology Co., Ltd. and its wholly-owned subsidiaries Qingdao Health Insurance National Engineering Technology Research Center Co., Ltd. and Qingdao Kangdian Animal Pharmaceutical Co., Ltd. as three new veterinary drugs, and recently announced the issuance of the “New Veterinary Drug Registration Certificate”.
Weilan Biotech (603739.SH): Wholly-owned subsidiary obtains a new veterinary drug registration certificate
On January 2, Gelonghui Biotech (603739.SH) announced that after review by the Ministry of Agriculture and Rural Affairs, it approved the “Little Goose Fever Freeze-dried Egg Yolk Antibody” jointly declared by Qingdao Weilan Animal Health Group Co., Ltd., a wholly-owned subsidiary of Qingdao Weilan Biology Co., Ltd. and other organizations, as three new types of new veterinary drugs, and recently announced the issuance of the “New Veterinary Drug Registration Certificate”.
These 4 Measures Indicate That Qingdao Vland Biotech (SHSE:603739) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Blue Biotech (603739.SH): The synthetic biotechnology innovation laboratory disclosed earlier is mainly used to develop functional proteins, sweeteners, etc.
On December 26, Gelonghui (603739.SH) announced an announcement of abnormal fluctuations in stock trading. Recently, the company noticed that the Internet and some media published reports on “synthetic biology”. The company's main business is R&D, production and sales of enzyme preparations, microecological preparations, and animal health products. According to the company's 2022 annual report, revenue from enzyme preparations was 421.684 million yuan, accounting for 37.16% of main business revenue; revenue from microecological products was 251.0956 million yuan, accounting for 22.13% of main business revenue; revenue from animal health products was 299.963 million yuan
Blue Biotech (603739.SH): Plans to suspend construction of microecological formulation research and industrialization projects
Gelonghui (603739.SH) announced on November 2, that due to the cyclical nature of project construction and operation, according to the business development plans of the two parties, after careful analysis, Azure Biotech Group and ADM Singapore signed the “Supplement Agreement 2 to the Revised Shareholder Agreement” and the “Shareholders' Meeting Resolution” on November 2, 2023. The two sides intend to suspend the construction of microecological formulation research and industrialization projects, and will adjust the joint venture's business plan according to the actual situation. Other cooperation projects between Azure Biotech and ADM are progressing smoothly. Construction of the project has been suspended and joint venture plans are planned
Net profit of 55.32 million yuan for the first three quarters of the year released by 603739.SH increased 2.05% year-on-year
Azure Biotech (603739.SH) disclosed its report for the third quarter of 2023. The company achieved operating income during the reporting period...
Analysis
Price Target
No Data
